On March 9, 2026, Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers. The same day, the two companies announced a partnership that fundamentally changes how millions of Americans access GLP-1 weight loss medication. Hims will stop advertising compounded semaglutide, transition patients to FDA-approved Wegovy, and become an authorized distribution channel for Novo Nordisk's branded products.
This is not a minor business deal. Hims was the largest telehealth seller of compounded semaglutide in the United States. Their pivot away from compounding — combined with the FDA's accelerating crackdown — signals that the era of cheap, unregulated GLP-1 alternatives is ending. Here is exactly what happened, what it means for patients, and what your options are now.
What Happened: The Lawsuit, the Deal, and the Pivot
In February 2026, Novo Nordisk sued Hims & Hers for what it called mass illegal compounding after Hims launched a $49 off-brand version of the Wegovy pill — roughly $100 less than the branded version. The lawsuit alleged patent infringement and sought to shut down Hims' compounded semaglutide business entirely.
Less than a month later, Novo dropped the case. Instead of fighting in court, the two companies struck a deal. Hims would stop marketing compounded semaglutide and become an authorized seller of FDA-approved Novo Nordisk products. In return, Hims gets access to branded Wegovy at preferential pricing and avoids what could have been an existential legal battle.
The strategic logic is clear for both sides. Novo gets the largest telehealth platform in America selling its branded drugs instead of undercutting them. Hims gets legal certainty, access to FDA-approved products, and avoids the regulatory risk that was already threatening its compounding business.
What Hims Offers Now
As of late March 2026, Hims & Hers now sells FDA-approved Wegovy in multiple forms through its platform. Here is what is available:
Wegovy Pill — Starting at $149 per month for the medication, plus a $39 first month membership fee that renews at $149 per month. Your effective cost for the first month is $188, then $298 per month ongoing (medication plus membership).
Wegovy Pen (injectable) — Starting at $199 per month for the medication, plus the same membership fee. Your effective cost is $238 first month, then $348 per month ongoing.
What the membership includes: Telehealth consultations with licensed providers, ongoing clinical support, prescription management, and medication delivery. The membership is billed separately and does not guarantee a prescription — you still need to qualify medically.
Hims also advertises Wegovy injections at 50 percent off retail price, which positions them below traditional pharmacy pricing but above the compounded alternatives that are being phased out.
For a full breakdown of every provider's current pricing, see our [cost tracker](/cost).
The Novo Nordisk Wegovy Subscription Program
The Hims deal is part of a broader Novo Nordisk strategy. On March 31, 2026, Novo launched a multi-month Wegovy subscription program through several authorized telehealth partners.
Launch partners: Ro, WeightWatchers, and LifeMD went live on March 31. Hims, Sesame, and other providers are coming online soon.
Pricing tiers:
12-month plan — $249 per month for either the Wegovy injection or pill. This is the best value, saving up to $1,200 per year on the injection and $600 per year on the pill compared to standard self-pay pricing.
6-month plan — Slightly higher monthly cost, still discounted from retail.
3-month plan — Smallest commitment, smallest discount.
Key details: Pricing stays fixed even if your dose changes during the subscription. The program targets self-pay patients — if you have commercial insurance, you may pay as little as $25 per month through Novo's existing savings card program. For a comparison of all Wegovy pricing options, check our [Wegovy cost analysis](/cost/wegovy).
What Happens to Compounded Semaglutide Patients
If you are currently on compounded semaglutide through Hims, here is what to expect:
Hims will not cut you off immediately. The company has stated it will continue to provide compounded semaglutide on a limited scale through the platform. However, it will no longer advertise or promote these options. Existing patients will receive information about transitioning to FDA-approved alternatives.
Your compounded supply is shrinking. Even if Hims continues filling existing prescriptions for now, the FDA's enforcement wave is squeezing compounders across the industry. Over 40 compounding pharmacies have received warning letters since late 2025, and the semaglutide shortage that originally justified 503A/503B compounding exemptions has been resolved. The legal basis for compounded semaglutide is eroding fast.
Your transition options are better than ever. A year ago, switching from compounded semaglutide ($150 per month) to branded Wegovy ($1,350 per month) was financially impossible for most patients. Today, you can get Wegovy for $249 per month through the subscription program, Foundayo for $149 per month through LillyDirect, or wait for the Medicare Bridge Program at $50 per month starting July 1. The price gap that made compounding essential has collapsed. Read our [GLP-1 price war analysis](/blog/glp1-price-war-foundayo-wegovy-april-2026) for the full picture.
Who Else Is in Novo's Authorized Network
Hims is not the only telehealth platform making this transition. The broader landscape is shifting fast:
Ro — Live on the Wegovy subscription program since March 31. Offers Wegovy alongside its existing weight loss platform. One of the earliest Novo partners.
WeightWatchers — Also live since March 31. Integrates Wegovy prescriptions with its behavior change and nutrition coaching program.
LifeMD — Third launch partner, live March 31. Offers Wegovy through its telehealth platform with clinical support.
Sesame — Expected to join the authorized network soon. Currently offers GLP-1 consultations at competitive pricing.
For our independent comparison of all these providers — including safety ratings, pricing, and what is actually included in each plan — see our [best GLP-1 providers ranking](/best).
What This Means for the GLP-1 Market
The Hims-Novo deal is a watershed moment for three reasons.
First, compounding is being squeezed from both sides. The FDA is sending warning letters and the major telehealth platforms are voluntarily exiting. Patients who rely on compounded semaglutide should treat this as a countdown, not a permanent option.
Second, branded GLP-1 prices are falling fast. Wegovy at $249 per month, Foundayo at $149 per month, Medicare Bridge at $50 per month — the price floor has dropped by 75 percent in six months. Competition between Novo Nordisk and Eli Lilly is driving this, and it is not done.
Third, telehealth platforms are consolidating around branded products. The wild west era of compounded GLP-1 telehealth is ending. What replaces it is a more regulated, more expensive, but more predictable market where patients get FDA-approved medications through authorized channels.
What You Should Do Now
If you are on compounded semaglutide through Hims: Start researching your transition options now. You are not being cut off today, but the writing is on the wall. Compare the Wegovy subscription at $249 per month versus Foundayo at $149 per month — for many patients, Foundayo is the better deal since it is a simple daily pill with no fasting requirement.
If you are considering starting GLP-1 therapy: This is actually the best time to start. You have more affordable, FDA-approved options than at any point in history. Check our [cheapest GLP-1 options page](/cheapest) for the current best deals.
If you are on Medicare: Wait for July 1. The Bridge Program will cover Wegovy, Zepbound, and Foundayo at $50 per month. Unless your doctor recommends starting sooner for medical reasons, waiting 12 weeks saves you thousands. Read our [Medicare GLP-1 Bridge guide](/blog/medicare-glp1-bridge-what-to-know).
If you want to compare all options side by side: Our [provider comparison page](/compare) lets you evaluate every telehealth provider by pricing, medication type, clinical support, and user ratings.
The compounding era gave millions of Americans access to GLP-1 therapy they could not otherwise afford. That chapter is closing. But what replaces it — branded medications at $149 to $249 per month through major telehealth platforms — is more sustainable, more regulated, and for most patients, a better long-term option.